Driehaus Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Driehaus Capital Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-107,591	Closed	-$1.72M	–	624
2015 Q1	$1.72M	Sell	107,591 -1,631	-1%	-$29K	0.06%	350
2014 Q4	$1.95M	Buy	109,222 +17,384	+19%	+$217K	0.08%	316
2014 Q3	$922K	Sell	91,838 -48,276	-34%	-$585K	0.04%	438
2014 Q2	$2.19M	Sell	140,114 -201,416	-59%	-$2.85M	0.07%	327
2014 Q1	$6.34M	Buy	+341,530	New	+$6.84M	0.2%	141

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Driehaus Capital Management's PETX Position: Q2 2015 in Review

Driehaus Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2015, closing a stake of 107,591 shares — an estimated $1.72M sold.

Driehaus Capital Management first reported a position in PETX in Q1 2014 and held it in 5 quarters. The position peaked at $6.34M in Q1 2014. 92 funds tracked by Wall St. Rank hold PETX as of Q2 2015.

Driehaus Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
Driehaus Capital Management sold 107,591 Aratana Therapeutics, Inc. shares in Q2 2015, an estimated $1.72M.
Driehaus Capital Management first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 5 quarters.
Driehaus Capital Management's Aratana Therapeutics, Inc. position peaked at $6.34M in Q1 2014.
92 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2015.

Based on Driehaus Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.